| Detailed information |
|---|
| CancerLivER ID | 2163 |
| Biomarker | miR-525-3p |
| Biomarker Name/Symbol (given in Publication) | miR-525-3p |
| Biomolecule | miRNA |
| Subject | Human |
| Degree of Validity | Predictor of poor prognosis and validated on independent dataset |
| Experimental Condition | HCC v/s other liver disease (cirrhosis/dysplasia); predict survival and recurrence of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 22429613 |
| Type of Biomarker | Prognostic |
| Pathway | TGF-b and WNT signals |
| Cohort | The training cohort: 60 patients serologically positive for HCV infection: (i) 10 end-stage cirrhosis (ii) 10 cirrhosis associated with HCC samples at a distance of at least 3 cm; (iii) 5 low-grade dysplastic nodules; (iv) 5 high-grade dysplastic nodules; (v) 10 early HCCs and (vi) 20 progressed HCC |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2012 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |